24/7 Patient Assistance: 760-405-8205

Peter Curtin, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

  • Bio & Insurance Information

    Dr. Peter Curtin graduated from the SUNY Upstate Medical University. He completed both his internship and residency program at the University of North Carolina Hospitals. Then, he did a fellowship at the University of California San Francisco. He is specialized in Medical Oncology and board certified in Internal Medicine, Hematology and Oncology. Dr. Curtin has been in practice for more than 20 years and is affiliated with the UC San Diego Health System. During his career, he has also contributed to 15 clinical research publications.

  • Education & Training


    SUNY Upstate Med Univ Graduated in 1979

    Medical School


    University Of North Carolina Hospitals Completed in 1980



    University Of North Carolina Hospitals Completed in 1982



    University Of California-San Francisco Completed in 1985


  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Hematology

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    UC San Diego Health System

    Languages: English/Spanish

    (858) 657-7000

    200 West Arbor Drive

    San Diego, California 92103

    Read More
  • Publications & Memberships

    Dr. Peter Curtin has contributed to 3 publications.

    Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.

    Brammer, J. E.,Stentz, A.,Gajewski, J.,Curtin, P.,Hayes-Lattin, B.,Kovacsovics, T.,Leis, J. F.,Meyers, G.,Nemecek, E.,Subbiah, N.,Frires, R.,Palmbach, G.,Avraham, G. P...; Biol. Blood Marrow Transplant.. 2014 Dec 03.

    See more >>

    Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21).

    Nguyen, J. C.,Kubik, M. J.,Broome, H. E.,Curtin, P. T.,Dell'Aquila, M. L.,Wang, H. Y.; Pathol. Res. Pract.. 2015 Aug 25.

    See more >>

    NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

    Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO...; J Natl Compr Canc Netw. 2016-12-01.

    See more >>